Comparative profiling of immune genes improves the prognoses of lower grade gliomas.

ABSTRACT:

Objective

Lower grade gliomas (LGGs), classified as World Health Organization (WHO) grade II and grade III gliomas, comprise a heterogeneous group with a median survival time ranging from 4-13 years. Accurate prediction of the survival times of LGGs remains a major challenge in clinical practice.

Methods

We reviewed the expression data of 865 LGG patients from 5 transcriptomics cohorts. The comparative profile of immune genes was analyzed for signature identification and validation. In-house RNAseq and microarray data from the Chinese Glioma Genome Atlas (CGGA) dataset were used as training and internal validation cohorts, respectively. The samples from The Cancer Genome Atlas (TCGA) and GSE16011 cohorts were used as external validation cohorts, and the real-time PCR of froz

SUBMITTER: Wang Z 

PROVIDER: S-EPMC9088193 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature